LEAP2 Investigated to Block Ghrelin Receptor in Semaglutide-Treated Obesity Patients
Background
Individuals with obesity often struggle with persistent hunger signals, even when using effective weight-loss medications like semaglutide, a GLP-1 receptor agonist. While semaglutide primarily works by enhancing satiety and reducing appetite, the ghrelin system (often called the 'hunger hormone' system) might still contribute to appetite regulation. This study aims to clarify how the ghrelin system functions when appetite is suppressed by semaglutide treatment, exploring if additional hunger signals remain active.
Results
As this study is currently recruiting (expected completion: 2026-02-01), no specific findings are available yet. However, the investigators aim to measure key physiological responses to understand the interaction between semaglutide and ghrelin signaling. They will assess food intake, appetite sensations (e.g., hunger, fullness), glucose metabolism, and hormonal responses in participants. The primary objective is to determine if antagonizing the ghrelin receptor with LEAP2 can further modulate appetite and metabolic parameters in individuals already on semaglutide. The study's most important aim is to clarify how the ghrelin system functions when appetite is suppressed by semaglutide treatment, and whether additional hunger signals remain active during GLP-1 treatment.
Why It Matters
Understanding the interplay between GLP-1 receptor agonists like semaglutide and the ghrelin system is crucial for optimizing obesity treatments. If blocking the ghrelin receptor with LEAP2 proves beneficial, it could lead to enhanced appetite suppression and potentially greater weight loss for individuals with obesity. This research could inform the development of future combination therapies, potentially leading to novel clinical strategies for managing obesity. The findings will guide future research, including potential Phase II trials investigating LEAP2's efficacy and safety in larger human cohorts.